Hormone replacement therapy and breast cancer

Annals of Surgical Oncology

Volumn 6, Issue 2, 1999, Pages 208-217

  Pearlstone, David B ^a   Pearlstone, Melissa M ^b   Vassilopoulou Sellin, Rena ^a   Singletary, S Eva ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b MacGregor Medical Association   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer risk; Estrogen; Neoplasia; Selective estrogen receptor modulators

Indexed keywords

ALENDRONIC ACID; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; BELLADONNA ALKALOID; BELLERGAL; CALCITONIN; CLONIDINE; CONJUGATED ESTROGEN; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; ERGOTAMINE; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; ETIDRONIC ACID; FLUORIDE; PHENOBARBITAL; PHOSPHONIC ACID DERIVATIVE; PROGESTERONE; PROPRANOLOL; RALOXIFENE; RISEDRONIC ACID; TAMOXIFEN; VERALIPRIDE;

BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; ENDOMETRIUM CARCINOMA; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; FEMALE; HORMONE RESPONSE; HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0032964384     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0208-z     Document Type: Review

References (90)

1. Marchant DJ. Supplemental estrogen replacement. Cancer 1994; 74:512-7.
2. Marchant DJ. Estrogen-replacement therapy after breast cancer. Cancer 1993;71:2169-76.
3. Fisher B, Sherman B, Rockette H, Redmond C, Margolese R, Fisher ER. l-Phenylalanine mustard (l-PAM) in the management of premenopausal patients with primary breast cancer. Cancer 1979; 44:847-57.
4. Dnistrian AM, Schwartz MK, Fracchia AA, Kaufman RJ, Hakes TB, Currie VE. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 1983;51:803-7.
5. Samaan NA, de Asis DN, Buzdar AU, Blumenschein GR. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 1978;41:2084-7.
6. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute. Natl Cancer Inst Monogr 1986;1:105-9.
7. Wenger NK, Speroff L, Packard B. Cardiovascular health in women. N Engl J Med 1993;329:247-56.
8. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-30.
9. Stampfer MJ, Colditz GA, Willett WC. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62.
10. Vassilopoulou-Sellin R. Estrogen replacement therapy in women at increased risk for breast cancer. Breast Cancer Res Treat 1993; 28:167-77.
11. Stampfer MJ. Postmenopausal estrogen use in heart disease. N Engl J Med 1987;316:164-5.
12. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use in cardiovascular disease. Epidemiol Rev 1985;7:80-104.
13. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990; 81:1680-7.
14. Lieberman EH, Gerhard MD, Uehata A. et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41.
15. Bell DR, Rensberger HJ, Koritnik DR, Koshy A. Estrogen pretreatment directly potentiates endothelium-dependent vasorelaxation of porcine coronary arteries. Am J Physiol 1995;268:H377-83.
16. Theriault RL, Sellin RV. A clinical dilemma: estrogen replacement therapy in postmenopausal women with a background of primary breast cancer. Ann Oncol 1991;2:709-17.
17. Ettinger B, Genant HK, Cann CE. Long term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102:319-24.
18. Richelson LS, Wahner HW, Melton LJ, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984;311:1273-5.
19. Lippman ME, Dickson RB, Bates S. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 1986;7:59-70.
20. Welsch CW. Host factors effecting the growth in carcinogeninduced rat mammary carcinomas: a review and a tribute to Charles Brenton Huggings. Cancer Res 1985;45:3415-20.
21. Aitken SC, Lippman SE. Effect of estrogen and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res 1985;45:1611-8.
22. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982;2:5-73.
23. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
24. Dhodapkar MV, Ingle JN, Ahmann DL. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995;75:43-6.
25. Speroff L. Postmenopausal hormone therapy and breast cancer. Obstet Gynecol 1996;87:44s-54s.
26. Haagensen CD, Stout AP. Carcinoma of the breast: criteria of operability. Ann Surg 1943;118:859-70.
27. Peters WV. Carcinoma of the breast associated with pregnancy. Radiology 1962;78:18.
28. Harrington SW. Carcinoma of the breast: results of surgical treatment when the carcinomas occur in the course of pregnancy or lactation and when pregnancy occurred subsequent to operation (1920-1933). Ann Surg 1937;106:690-700.
29. Wallgren A, Silfversward C, Hultborn A. Carcinoma of the breast in women under 30 years of age. Cancer 1977;40:916.
30. DiSaia PJ. Hormone-replacement therapy in patients with breast cancer. Cancer 1993:71:1490-500.
31. Holleb AI, Farrow JH. The relation of carcinoma of the breast and pregnancy in 283 patients. Surg Gynecol Obstet 1962;115:65-71.
32. Cooper DR, Butterfield J. Pregnancy subsequent to mastectomy for cancer of the breast. Ann Surg 1970;171:429-33.
33. The Centers for Disease Control Cancer and Steroid Hormone Study. Long-term oral contraceptive use and the risk of breast cancer. JAMA 1983;249:1591-5.
34. Wingo PA, Lee NC, Ory H, Beral V, Peterson HB, Rhodes P. Age specific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol 1991;78:161-70.
35. Schlesselman JJ, Stadel BV, Murray P, Lai S. Breast cancer in relation to early use of oral contraceptives: no evidence of a latent effect. JAMA 1988;259:1828-33.
36. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987;257:209-15.
37. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
38. Skegg DCG. Potential for bias in case-control studies of oral contraceptives and breast cancer. Am J Epidemiol 1988;127:205-12.
39. Stadel BV, Rubin GL, Webster LA, Schlesselman JJ, Wingo PA. Oral contraceptives and breast cancer in young women. Lancet 1985;2:970-3.
40. Meirik O, Lund W, Adami HO, Bergstrom R, Christofferson T, Bergsjo P. Oral contraceptive use and breast cancer in young women: a joint national case-control study in Sweden and Norway. Lancet 1986;2:650-4.
41. Miller DR, Rosenberg L, Kaufmann DW, Schottenfeld D, Stolley PD, Shapiro S. Breast cancer risk in relation to early oral contraceptive use. Obstet Gynecol 1986;68:863-8.
42. McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M. Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer 1987;56:653-60.
43. Jick SS, Walker AM, Stergachis A, Jick H. Oral contraceptives and breast cancer. Br J Cancer 1989;59:618-21.
44. LaVecchia C, Parazzini F, Negri E, Boyle P, Gentile A, DeCarli A. Breast cancer and combined oral contraceptives: an Italian case-control study. Eur J Cancer Clin Oncol 1989;25:1613-8.
45. Olsson H, Moller TR, Ranstam J. Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. J Natl Cancer Inst 1989;81:1000-4.
46. Romieu I, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH. Prospective study of oral contraceptive use and risk of breast cancer in women. J Natl Cancer Inst 1989;81:1313-21.
47. Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 1989;59:613-7.
48. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and combined oral contraceptives: results from a multinational study. Br J Cancer 1990;61: 110-9.
49. Paul C, Skegg DCG, Spears GFS. Oral contraceptives and risk of breast cancer. Int J Cancer 1990;46:366-73.
50. Weinstein AL, Mahoney MC, Nasca PC, Leske MC, Varma AO. Breast cancer risk and oral contraceptive use: results from a large case-control study. Epidemiology 1991;2:353-8.
51. Hulka BS, Liu ET, Lininger RA. Steroid hormones and risk of breast cancer. Cancer 1994;74:1111-24.
52. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
53. Colditz GA, Stampfer MJ, Willett WC. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992;3:433-9.
54. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
55. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7:449-57.
56. Armstrong BK. Oestrogen therapy after the menopause: boon or bane? Med J Aust 1988;148:213-4.
57. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
58. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.
59. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R. Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992;79:286-94.
60. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1942;117:1016-37.
61. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-80.
62. Nachtigal MJ, Smilen SW, Nachtigal RAD, Nachtigal RH, Nachtigal LI. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992;80:827-30.
63. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
64. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
65. Roy JA, Sawka CA, Pritchard KI. Hormone replacement therapy in women with breast cancer: do the risks outweigh the benefits? J Clin Oncol 1996;14:997-1006.
66. Powles TJ, Hickish T, Casey S, O'Brien M. Hormone replacement after breast cancer. Lancet 1993;342:60-1 (letter).
67. DiSaia PJ, Odicino F, Grosen EA, Cowan B, Pecorelli S, Wile AG. Hormone replacement therapy in breast cancer. Lancet 1993;342: 1232 (letter).
68. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165:372-5.
69. Stoll BA, Parbhoo S. Treatment of menopausal symptoms in breast cancer patients. Lancet 1988;1:1278-9.
70. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with a prior diagnosis and treatment of breast cancer. Gynecol Oncol 1997;65:89-93.
71. Ludwig Breast Cancer Study Group. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1985;3:1059-67.
72. Ravdin RG, Lewison EF, Slack NH, Gardner B, State D, Fisher B. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet 1970; 131:1055-64.
73. Lonning PE, Helle SI, Johannessen DC, Ekse D, Adlercreutz H. Influence of plasma estrogen levels on the length of disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 1996;39:335-41.
74. Vassilopoulou-Sellin R, Theriault RL. Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. Monogr National Cancer Inst 1994;16:153-9.
75. Love SM, Dr. Susan Love's hormone book. New York: Random House, 1997.
76. Hendrix SL. Nonestrogen management of menopausal symptoms. Endocrinol Metab Clin North Am 1997;26:379-90.
77. Seeman E. Osteoporosis: trials and tribulations. Am J Med 1997; 103:745-878.
78. Lane JM. Osteoporosis: medical prevention and treatment. Spine 1997;22:32S-7S.
79. Love RR, Mazess RB, Barden HS. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
80. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish tamoxifen trial: the Scottish Breast Cancer Committee. Br Med J 1991;303:435-7.
81. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86: 527-37.
82. Morgan RW. Risk of endometrial cancer after tamoxifen treatment. Oncology 1997;11:25-33.
83. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res 1997;48:155-63.
84. Palkowitz AD, Glasebrook AL, Thrasher KJ, et al. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenol]-2-(4-hydroxyphenyl)]beno[b] thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem 1997;40:1407-16.
85. Bryant HU, Dere WH. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 1998;217:45-52.
86. Gradishar WJ, Glusman JE, Vogel CL, et al. Raloxifene HCl, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer. Breast Cancer Res Treat 1997;46:53.
87. Delmas PD, Bjarnson NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
88. The American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992;117:1038-41.
89. United Kingdom National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. Lancet 1989;1:973-82.
90. Katsung BG, ed. Introduction to endocrine pharmacology in basic and clinical pharmacology, ed. 3. Norwalk, CT: Appleton & Lange, 1987.